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INTRODUCTION: Chronic thromboembolic pulmonary hypertension is a disease affecting approximately 4,000 people per
year in the United States. The incidence rate in Brazil, however, is unknown. The estimated survival for patients with
chronic thromboembolic pulmonary hypertension without treatment is approximately three years. Pulmonary
thromboendarterectomy for select patients is a potentially curative procedure when correctly applied. In Brazil, the
clinical and hemodynamic profiles of chronic thromboembolic pulmonary hypertension patients have yet to be described.
OBJECTIVES: To evaluate the clinical and hemodynamic characteristics of chronic thromboembolic pulmonary
hypertension patients scheduled for pulmonary thromboendarterectomy in a referral center for chronic
thromboembolic pulmonary hypertension treatment in Brazil.
METHODS: From December 2006 to November 2009, patients were evaluated and scheduled for pulmonary
thromboendarterectomy. The subjects were classified according to gender, age and functional class and were tested
for thrombofilia and brain natriuretic peptide levels.
RESULTS: Thirty-five consecutive chronic thromboembolic pulmonary hypertension patients were evaluated. Two
patients tested positive for schistosomiasis, and 31 were enrolled in the study (19 female, 12 male). The majority of
patients were categorized in functional classes III and IV. Hemodynamic data showed a mean pulmonary vascular
resistance (PVR) of 970.8 ¡ 494.36 dynas?s?cm-5 and a low cardiac output of 3.378 ¡ 1.13 L/min. Linear regression
revealed a direct relation between cardiac output and pulmonary vascular resistance. Paradoxical septal movement
was strongly correlated with pulmonary vascular resistance and cardiac output (p = 0.001). Brain natriuretic peptide
serum levels were elevated in 19 of 27 patients.
CONCLUSIONS: In a referral center for pulmonary hypertension in Brazil, chronic thromboembolic pulmonary
hypertension patients evaluated for pulmonary thromboendarterectomy had a hemodynamically severe status and
had elevated brain natriuretic peptide serum levels. There was a predominance of females in our cohort, and the
prevalence of hematological disorders and schistosomiasis was low (less than 10%).
KEYWORDS: Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial Hypertension; Pulmonary
Thromboendarterectomy; Pulmonary Hemodynamics; Schistosomiasis.
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INTRODUCTION
Pulmonary arterial hypertension (PAH), defined as a
mean pulmonary arterial pressure $ 25 mmHg at rest or .
30 mmHg during exercise,1 is a rare disease that leads to
heart failure and death. There are many diseases that cause
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PAH, including idiopathic pulmonary arterial hypertension
(IPAH). In addition, PAH is associated with anorexigen
exposure, sleep apnea, collagenoses, chronic thromboembolic
pulmonary hypertension (CTEPH) and schistosomiasis.1,2
Schistosomiasis is an important cause of PAH in the
developing world.3,4 Unlike other countries, schistosomia-
sis-associated PAH (Sch-PAH) was found to be more
prevalent than PAH associated with anorexigen exposure
at a referral center for PAH in Sao Paulo.3,5
CTEPH is a disease that affects approximately 4,000
people per year in the United States, and its incidence rate is
1–5% within two years after the thromboembolic event.6–8
The incidence in Brazil is currently unknown; however, if
the same numbers were used to forecast the incidence in
Brazil, there would be around 1,525 new CTEPH cases each
year in the country. CTEPH is caused by clot obstruction in
pulmonary arteries, leading to an increased pulmonary
vascular resistance (PVR) and pulmonary hypertension
(PH).6,7 CTEPH is a severe disease characterized by
persistent PAH after at least three months of an acute
pulmonary thromboembolic episode.9 The average survival
of patients with CTEPH without treatment is approximately
three years. Pulmonary thromboendarterectomy (PTE) for
select patients is a potentially curative procedure when
correctly indicated,10 leading to a significant improvement
in the quality of life.2 The success of PTE surgery is
dependent on patient suitability. There is, however, no age
restriction for this intervention.11,12
In Brazil, the clinical and hemodynamic profiles of CTEPH
patients have yet to be described. PAH due to schistosomiasis
is frequent and may be a confounding factor in the indication
of PTE, given that PAH can sometimes be characterized by
in situ thrombosis and the appearance of apparent clots in
the pulmonary arteries on chest angiotomography (Figure 1).
Important distal vessel remodeling, however, can be
observed. Therefore, PTE indication may be incorrect for
such patients because PAH will not decrease after surgical
treatment, contrary to what is observed in the majority of
subjects who undergo PTE. Because of these issues, it is
important to establish a clinical and hemodynamic profile of
CTEPH patients in Brazil who are scheduled for PTE.
The aim of this study was to evaluate the clinical and
hemodynamic characteristics of patients with CTEPH who
are scheduled for PTE at a referral center for treatment of
this disease in Brazil.
METHODOLOGY
The present investigation was approved by the Research
Ethics Committee of Sa˜o Paulo Medical School, and
informed written consent was obtained from all patients.
This study was a transversal retrospective study with a
prospective insertion.
From December 2006 to November 2009, patients with
PAH were evaluated and scheduled for PTE. Thirty-five
consecutive patients with CTEPH were eligible for PTE.
Diagnosis of CTEPH was established by transthoracic
echocardiography with Doppler, showing PH defined by a
right ventricular systolic pressure (RVSP) . 35 mmHg,
chest angiotomography, pulmonary angiography images
compatible with thrombus and right-sided heart catheter-
ization (RHC). Schistosomiasis was established by medical
history, epidemiological characteristics and positive stool
analysis for S. mansoni ova. Patients were classified
according to gender, age and functional class.
Inclusion criteria consisted of operable CTEPH, charac-
terized by central thrombotic lesions that are surgically
accessible; a PVR . 300 dynas?s?cm-5 (or 3.75 Woods); a
mean pulmonary artery pressure (mPAP) $ 25 mmHg in
the presence of a pulmonary capillary wedge pressure ,
15 mmHg and a signed consent form.
Patients were excluded if they had a predominance of
peripheral vascular obstruction on angiography; a creati-
nine clearance lower than 60 ml/min with a reduced or
normal BNP level; or important comorbidities, including left
heart failure, severe obstructive or restrictive pulmonary
disease or neoplasia.
Clinical and functional evaluation
A medical history was taken from each patient, followed
by a physical examination. Demographic data, the presence
of other diseases, the use of medications and the presence/
absence of dyspnoea, hemoptysis, syncope, cough, thoracic
pain, dizziness and palpitations were recorded. Patients
were classified according to severity using the New York
Heart Association functional classification (modified) (World
Health Association), and a 6-minute walk test (6MWT) was
performed based on the American Thoracic Society protocol.13
Hemodynamic measurements and acute vasodilator
testing
After clinical, functional and radiological evaluation,
PAH patients were submitted to RHC according to a
previously described protocol.14 Briefly, for RHC, a triple-
lumen balloon-tipped catheter was inserted through the
internal jugular vein (Swan-Ganz, model 131F7; Baxter,
Edwards Critical Care Division, Irvine, CA). The pulmonary
arterial pressure (PAP), pulmonary vascular resistance
(PVR), pulmonary arterial occlusion pressure (PAOP) and
cardiac output (CO) were measured. The indexed PVR
(IPVR) and cardiac index (CI) were also calculated.
Hemodynamic data were collected at baseline and after
the administration of inhaled nitric oxide (NO) for 10 min-
utes. A complete hemodynamic status response was defined
by a decrease in mPAP of at least 10 mmHg and an absolute
Figure 1 - A contrast-enhanced spiral CT scan showing an eccentric
filling defect along the lateral margin of the right pulmonary
artery. The patient was a 53-year-old male with schistosomiasis,
pulmonary hypertension and lung vessel remodeling.
Evaluation of CTEPH patients scheduled for PTE
Terra-Filho M et al.
CLINICS 2010;65(11):1155-1160
1156
decrease of mPAP under 40 mmHg in the presence of
normal or increased CO during NO inhalation.
Laboratory tests
Laboratory exams consisted of quantification of serum
protein S and C, antithrombin III, factor V Leiden, anti-
cardiolipin antibodies, lupus anticoagulant and antipho-
spholipid antibody and a determination of the presence of
mutant prothrombin, homocystein and BNP serum.
Creatinine clearance was also calculated. Stool sample
analyses for S. mansoni ova were obtained.
Statistical analysis
Continuous data are summarized as the mean and
standard deviation (mean¡ SD) or, in the case of a skewed
distribution, as the median (25th percentile–75th percentile).
Pearson correlation coefficients and regression analyses
were calculated for the hemodynamic data. A p-value of
, .05 was considered significant.
RESULTS
Patients
Thirty-five consecutive CTEPH patients were evaluated,
and 31 were enrolled in the current study. Four patients
were excluded, two who refused to be submitted to the RHC
and two who tested positive for schistosomiasis. The
characteristics of the patients enrolled are summarized in
Table I, all submitted to clinical evaluation and haemodi-
namic studies, but the complete data were obtained in only
27 patients (technical limitations). Nineteen subjects were
female, the majority of the patients were categorized in
World Health functional classes III and IV, according to
the diagnostic criteria defined by the World Health
Organization.13,15 All patients had severe PH (Table I).
Hemodynamic measurements
The hemodynamic data showed an increased PVR and
low CO in the CTEPH patients (Table II). Twelve patients
had a POAP higher than 14 mmHg. All patients had a
negative acute reactivity test. There was a significant
correlation between sPAP and RVSP (r = 0.44, p = 0.023).
As expected, linear regression revealed a direct
relation between CO and PVR (Figure 2)
We found that 18 of 27 patients had paradoxical septum
motion (PSM) as determined by echocardiogram. PVR had a
strong correlation with PSM (r = 0.63; p = 0.001) (Fig. 3) and
CO (r = -0.61; p = 0.001).
Laboratory findings
Twelve of 31 patients had hematological disorders,
including the presence of factor V Leiden (n = 1), antithrom-
bin III deficiency (n = 1), the presence of prothrombin
mutation (n = 1), hyperhomocysteinemia (serum levels higher
than 19 mmol/L) (n = 5), the presence of anticardiolipin and
antiphospholipid antibodies (n = 3), the presence of the
antinuclear factor (n = 3) and protein S deficiency (n = 1).
None of the patients had protein C deficiency.
BNP serum levels were elevated in 19 of 27 patients
[median: 138 (28–805) pg/mL], and BNP serum levels
significantly correlated with the presence of PVR (r = 0.47,
p = 0.018). BNP also had correlating trend with CO (r = -0.39,
p = 0.053). No correlations were found between BNP and
WHO functional class or 6MWT and RVSP.
DISCUSSION
In the present study, we found a predominance of women
with CTEPH, consistent with data described by Jamieson
et al.16 Despite the fact that the hospital at which this study
was carried out is a referral center for CTEPH, very few
patients had Sch-PAH. One of the possible explanations for
this finding is that this hospital is also a referral center for
PAH associated with causes other than CTEPH, and only
patients that have central clots in their pulmonary arteries
are sent to our CTEPH service. The second reason is that
two of the authors (MTF and FBJ) have given lectures at
national meetings for over 10 years to draw attention to this
little-known disease and to encourage other doctors to send
their CTEPH patients to our specialized service.
The majority of patients were categorized in WHO
functional classes III or IV, which is explained by the fact
that patients with serious vascular diseases and signs of
right heart failure are always recommended to referral
centers.10 This often occurs too late because the disease
is not well known, and the diagnosis is difficult. The
presence of high RVSP and PSM in these patients confirms
this finding. Patients with PAH have an increase in right
ventricle (RV) pressure and prolonged isovolumetric
contraction. As a consequence, the diastolic RV pressure
becomes higher than in the left ventricle, leading the
septum to move paradoxically. Mori et al.17 described
PSM as a low cardiac index predictor. In this study,
PSM was significantly correlated with CO and PVR,
Table 1 - Baseline patient characteristics.
Patients (n) 31
Gender (F: M) (n) 19: 12
Age, years* 51.5 ¡ 13
6MWT, meters* 346.9 ¡ 121.3
Functional Class WHO (I–II): (III–IV) (n) 10: 18
Ecocardiogram findings
RVSP, mmHg (n = 28)* 83.6 ¡ 25.2
EF, % (n = 30)*# 0.67 ¡ 0.06
PSM (yes: no) (n = 27) 18: 9
RVSP: right ventricle systolic pressure; EF: ejection fraction; PSM:
paradoxical septal motion.
*Data shown as the mean ¡ SD.
#One patient had a normal EF, but the percentage was not calculated.
Table 2 - Hemodynamic variables at baseline and after
vasoreactivity testing.
(n = 29) Baseline After NO inhalation
CO (L/min) 3.378 ¡ 1.13 3.57 ¡ 0.87
sPAP (mmHg) 89.41 ¡ 26.32 83.36 ¡ 25.15
dPAP (mmHg) 32.89 ¡ 10.03 30.71 ¡ 12.5
mPAP (mmHg) 54.98 ¡ 15.33 50.14 ¡ 14.05
PAOP (mmHg) 15.86 ¡ 10.09 13.33 ¡ 4.84
PVR (dynas?s?cm-5) 970.8 ¡ 494,36 894,83 ¡ 439,04
CO: Cardiac output; sPAP: systolic pulmonary artery pressure; dPAP:
diastolic pulmonary artery pressure; mPAP: mean pulmonary artery
pressure; PAOP: pulmonary artery occlusion pressure; PVR: pulmonary
vascular resistance. Data shown as the mean ¡ SD.
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Figure 3 - Correlation between PVR and PSM.
Figure 2 - Linear regression of CO and PVR.
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indicating that patients with PSM were hemodynamically
more deteriorated.
In walking tests, it has been shown that 345 meters is the
cut-off point to predict survival post-PTE.18 Our patients
walked a mean distance of 347 meters. It is reasonable to
believe that our patients will not have an excellent post-PTE
prognosis, as along with their poor 6MWT scores, their
mean PVR was greater than 970 dynas?s?cm-5. As indicated
by Dartevelle et al., patients with a PVR lower than
900 dynas?s?cm-5 have a 4% mortality rate, whereas patients
with a PVR between 900–1,200 dynas?s?cm-5 have a more
than 10% mortality rate.19 In the present study, 33% of the
patients had a PVR greater than 1,100 dynas?s?cm-5. This
finding confirms that patients are typically referred in an
advanced stage of disease, which may explain the high
mortality rate found in this center (over 17%; data reflect
patients not included in this research).
We also found that the patients had a hemodynamically
severe status and had elevated PVR and low CO. This
inverse relationship was significant and confirms previously
published findings.20
Previous work by Skoro-sajer et al. showed that changes
in mPAP during the NO vasoreactivity test are associated
with better outcomes following surgery.21 In our study,
however, none of the patients had a positive test. Similar to
our results, Ulrich et al. found positive NO vasoreactivity
tests in only 6% of CTEPH patients (122 patients).22 It is
possible that an increased number of patients could help
explain the true significance of the NO vasoreactivity test in
the prognosis for patients being submitted to PTE.
It was surprising to observe that the POAP was elevated
in 12 patients, revealing the association of a postcapillary
component. It has been hypothesized that CTEPH may be
related to left ventricle diastolic dysfunction due to septum
compression and hypertrophy caused by increased RV
pressure or decreased LV filling.23,24
In addition, BNP or NT-proBNP serum levels have been
used as markers of ventricular dysfunction in left heart
disease and PAH.25–27 Nagaya et al.28 evaluated BNP serum
levels in 34 CTEPH patients before and after PTA and found
a significant correlation between BNP serum levels and PVR
before and after surgery. Reesink et al.29 showed findings
consistent with those of Nagaya et al., and the present study
also showed that BNP is significantly correlated with PVR
and has a trend to correlate with CO. These results suggest
that BNP is a marker of severity in CTEPH, as observed in
other studies.26–28
Hematological disorders are risk factors for CTEPH;
however, the prevalence of these disorders is not high.30,31
Wolf et al. showed that the frequency of antiphospholipid
antibodies in CTEPH was 20% in a population of 116
patients,32 similar to that found in our data.
The current study is not without limitations. For instance,
our sample size was very small, part of our data was
collected retrospectively, and our patients were not evalu-
ated after PTE.
CONCLUSIONS
The CTEPH patients evaluated for PTE were predomi-
nantly female. The patients had a clinically and hemodyna-
mically severe status and had elevated BNP serum levels.
The prevalence of schistosomiasis and hematological dis-
orders was low (less than 10%).
These findings lead us to deduce that patients arrive at
our specialized center with a specific and advanced disease.
We therefore emphasize the importance of an early and
precise diagnosis to improve the survival of CTEPH patients
by referring them before they reach an advanced stage.
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